Acceptance of Telemedicine in Dermatology Patients, Physicians and Medical Staff

Overview

This study is to investigate the current use and intention to use of teledermatology in Swiss dermatology patients, dermatologists, other physicians and medical staff.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 2020

Detailed Description

Telemedicine, the use of telecommunication and information technology to provide clinical health care from a distance, has become an increasing role in basic medical care internationally. Telemedicine is particularly suitable for skin diseases. In order to improve the use of evidence-based telemedicine, the Swiss patients` preferences regarding teledermatology versus face-to-face consultations and the patients` and physicians` determinants of acceptance for teledermatology are investigated in this study. Dermatology patients are asked to complete a newly-created 21-items-survey; Swiss dermatologists, other physicians and medical staff on telemedicine will complete a similar newly-created, 23-items-questionnaire. A descriptive statistical analysis (e.g. gender, age, place of residence (city or country), waiting time) will be performed.

Interventions

  • Other: data collection (21-items-patient descriptive survey)
    • Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor`s consultation. Following variables will be addressed: Demographic data of telemedicine users and non-users Subjective disease perception of the dermatology patients Use of internet, telemedicine and telemedicine insurance model Patients´ willingness for additional features of telemedicine Advantages and disadvantages telemedicine and face-to-face consultation Suitable fields of dermatology for telemedicine from the patient’s perspective Recommended structure of telemedical services by users and non-users
  • Other: data collection (23-items-physician descriptive survey)
    • To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed: Objective disease perception of the treating dermatologist (regarding the urgency of the patient`s medical examination, the functional impairment and cosmetic burden due to patient`s disease, the impairment of life quality due to patient`s disease and the estimation of the course of the patient`s disease) Suitable fields of dermatology for telemedicine from the physician’s and medical staff`s perspective

Arms, Groups and Cohorts

  • dermatology patients
  • physicians and medical staff

Clinical Trial Outcome Measures

Primary Measures

  • descriptive analysis: deviation in influencing factors for the acceptance of teledermatology
    • Time Frame: at baseline
    • Assessment of the deviation in influencing factors for the acceptance of teledermatology (subjective disease perception versus objective assessment by physicians)
  • descriptive analysis of the impact of medical education for the acceptance of telemedicine among dermatologists vs. other physicians vs. medical staff vs. patients
    • Time Frame: at baseline
    • Comparison of the impact of medical education for the acceptance of telemedicine among dermatologists vs. other physicians vs. medical staff vs. patients

Participating in This Clinical Trial

Inclusion Criteria

  • patients treated in the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich
  • dermatologists, other physicians and medical staff of the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich

Exclusion Criteria

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital, Basel, Switzerland
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Lara Valeska Maul, Dr. med., Principal Investigator, Department of Dermatology, University Hospital Basel
  • Overall Contact(s)
    • Lara Valeska Maul, Dr. med., +41 61 265 40 80, laravaleska.maul@usb.ch

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.